UBS Maintains a Buy on Genmab (GMAB) With a DKK2,500 PT

Genmab A/S (NASDAQ:GMAB) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 25, UBS analyst Xian Deng maintained a Buy rating on Genmab A/S (NASDAQ:GMAB) and set a price target of DKK2,500.00.

The company reported $715 million in revenue for the first three months of 2025 compared to $603 million in the same period last year. This translates to a growth of 19% or $112 million, which the company attributed to increased DARZALEX and Kesimpta royalties attained under its collaborations with Johnson & Johnson and Novartis Pharma AG, respectively. EPKINLY net product sales also contributed to this growth.

Royalty revenue for the quarter also rose to $589 million, experiencing an increase of $137 million, or 30%. This growth was driven by an increase in net sales of DARZALEX and Kesimpta.

Genmab A/S (NASDAQ:GMAB) is an international biotechnology company that develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes DARZALEX to treat certain indications of multiple myeloma, TEPEZZA for the treatment of thyroid eye disease, and Arzerra to treat certain indications of chronic lymphocytic leukemia.

While we acknowledge the potential of GMAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.